Michael L. Krychman, MD, and Jack D. Sobel, MD, review diagnostic criteria of diagnosis of RVVC and the impact of misdiagnosis.
Michael L. Krychman, MD: What are some of the challenges about diagnosing recurrent VVC [vulvovaginal candidiasis]? Do you think people are very aware in the community at large?
Jack D. Sobel, MD: The first issue really, as far as diagnosis is concerned, is so-called self-diagnosis. This is the ability of any individual woman to be able to diagnose with great certainty that her symptoms are attributable to a yeast. Self-diagnoses are remarkably inaccurate. I know there’s always going to be some argument from the people listening in on this, participants hearing this, watching this video, but really there are numerous good objective studies that show just how unreliable self-diagnosis is. That doesn’t mean patients, women, don’t have symptoms, it simply means that the symptoms are entirely nonspecific. There’s nothing unique to the symptoms that says, “Oh, I obviously do have a yeast infection.” Repeatedly, women are referred to me because of recurrent candida vaginitis, and when I start interrogating and talking to them, and getting a history, and we do the appropriate tests, we find that there’s a lot of overdiagnosis of recurrent infections and there are some elements of underdiagnosis, especially for chronic disease. But you’ve already outlined the various symptoms involved, so the next issue, as far as diagnosis is concerned, it’s not difficult to diagnose once the patient finds herself visiting a practitioner, and this is not a telehealth visit. Telehealth is a wonderful advance in medicine and science, but in the diagnosis of vaginitis it’s about 10 steps backwards. You cannot diagnose reliably any form of vulvovaginal disease without seeing a practitioner who takes a history and does a good physical examination as well as the appropriate immediate local tests that are available within the doctor’s office.
Michael L. Krychman, MD: I agree with you. The physical exam is invaluable and we’ll touch upon the concept of overdiagnosis, underdiagnosis in a little bit and how the impact of telehealth and teleprescribing, and you had mentioned that people are misdiagnosing or over the counter, we don’t have confirmation of diagnoses, so overdiagnosis. Every vaginitis is not yeast. Sometimes there’s BV [bacterial vaginosis]. Sometimes there’s a mixed infection. Sometimes it’s vulvovaginal atrophy. I think part of the issue that we are seeing is we have created this issue where there is a lot of telephone diagnosis and treatment because we didn’t have a choice with COVID-19, and then we’re overtreating. We’re seeing the emergence of resistance. We’re seeing more nonalbicans candidiasis. We’re seeing a variety of things that are changing in the landscape.
Transcript Edited for Clarity
Unveiling metabolic markers of Candida albicans infection
February 27th 2024Discover how metabolomics sheds light on potential biomarkers for early detection and treatment of Candida albicans-induced vulvovaginal candidiasis, offering crucial insights into the pathogenesis of this prevalent inflammatory condition.
Read More
Demystifying bacterial vaginosis: Understanding, treatment, and breaking stigmas
February 26th 2024Misunderstandings surrounding bacterial vaginosis can delay treatment, but advancements such as XACIATO offer effective solutions, emphasizing the importance of open communication and continued research for comprehensive women's health care.
Read More
Oteseconazole outperforms fluconazole in treating severe vulvovaginal candidiasis
January 31st 2024A phase 3 trial demonstrated that oteseconazole (VIVJOA; Mycovia Pharmaceuticals) capsules exhibit improved therapeutic and mycological cure rates to fluconazole for treating severe vulvovaginal candidiasis.
Read More